Literature DB >> 324689

Plasma protein binding of phenytoin and warfarin in patients undergoing renal transplantation.

I Odar-Cederlof.   

Abstract

The plasma protein binding of phenytoin and warfarin was studied in vitro by equilibrium dialysis at 37 degrees C in plasma from patients with chronic renal disease before and after renal transplantation. The plasma protein binding of these two drugs (which is decreased in the uraemic state), increased dramatically during the first 2 to 4 postoperative days and reached values slightly below normal on the 10th to the 15th postoperative day. This increase in binding is suggested to be due to the elimination of inhibiotrs of drug albumin binding, earlier shown to be present in uraemic serum.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 324689     DOI: 10.2165/00003088-197702020-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  23 in total

1.  Protein binding of salicylate in uremic and normal plasma.

Authors:  O Borgå; I O Cederlöf; V A Ringberger; A Norlin
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

2.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors:  M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal:  N Engl J Med       Date:  1971-07-29       Impact factor: 91.245

3.  Abnormal pharmacokinetics of phenytoin in a patient with uraemia.

Authors:  I Odar-Cederlöf; P Lunde; F Sjöqvist
Journal:  Lancet       Date:  1970-10-17       Impact factor: 79.321

4.  Influence of disease on binding of drugs to plasma proteins.

Authors:  M M Reidenberg; M Affrime
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

5.  Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding.

Authors:  I Odar-Cederlöf; O Borgå
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

Review 6.  The binding of drugs by plasma proteins.

Authors:  M C Meyer; D E Guttman
Journal:  J Pharm Sci       Date:  1968-06       Impact factor: 3.534

7.  Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults.

Authors:  M Ehrnebo; S Agurell; B Jalling; L O Boréus
Journal:  Eur J Clin Pharmacol       Date:  1971-09       Impact factor: 2.953

8.  Correlation between red cell and free plasma phenytoin levels in renal disease.

Authors:  A L Sherwin; C D Harvey; I E Leppik; A Gonda
Journal:  Neurology       Date:  1976-09       Impact factor: 9.910

9.  Fluid volume and albumin kinetics occurring with major surgery.

Authors:  R C Hoye; S H Bennett; G W Geelhoed; C Gorschboth
Journal:  JAMA       Date:  1972-12-04       Impact factor: 56.272

10.  Kinetics of salicylate elimination by anephric patients.

Authors:  D T Lowenthal; W A Briggs; G Levy
Journal:  J Clin Invest       Date:  1974-11       Impact factor: 14.808

View more
  9 in total

Review 1.  Diseases and drug protein binding.

Authors:  J P Tillement; F Lhoste; J F Giudicelli
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

Review 2.  Interrelationship between renal haemodynamics, drug kinetics and drug action.

Authors:  K L Duchin; R W Schrier
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

Review 3.  Clinical relevance of pharmacokinetics.

Authors:  G Tognoni; C Bellantuono; M Bonati; M D'Incalci; M Gerna; R Latini; M Mandelli; M G Porro; E Riva
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

4.  Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease.

Authors:  F Keller; M Maiga; H H Neumayer; H Lode; A Distler
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jul-Sep       Impact factor: 2.441

5.  Plasma protein binding of azapropazone in patients with kidney and liver disease.

Authors:  E Jähnchen; K J Blanck; K H Breuing; H J Gilfrich; T Meinertz; D Trenk
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

6.  Albumin binding in uraemia: quantitative assessment of inhibition by endogenous ligands and carbamylation of albumin.

Authors:  T J Dengler; G M Robertz-Vaupel; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics of phenytoin.

Authors:  A Richens
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

8.  Phenytoin binding to human albumin.

Authors:  M Lecomte; R Zini; P d'Athis; J P Tillement
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

Review 9.  Clinical pharmacokinetics in organ transplant patients.

Authors:  R Venkataramanan; K Habucky; G J Burckart; R J Ptachcinski
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.